SCHEMBL16237705

SCHEMBL16237705

O=C(c1cccnc1)c1ccco1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.61
POLB P06746 3/20 0.61
MEN1 O00255 3/20 0.61
ALDH1A1 P00352 3/20 0.59
TDP1 Q9NUW8 2/20 0.59
THRB P10828 1/20 0.59
APEX1 P27695 1/20 0.59
RECQL P46063 1/20 0.59
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.53
NPC1 O15118 1/20 0.53
TP53 P04637 1/20 0.53
ALOX15 P16050 1/20 0.53
RAB9A P51151 1/20 0.53
MAPK1 P28482 1/20 0.52
HPGD P15428 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
ADORA2A P29274 1/20 0.52
ADORA1 P30542 1/20 0.52
APP P05067 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Niacin SCHEMBL30309816 0.83 ALDH1A1 (0.68) KMT2APOLBMEN1ALDH1A1TDP1
SCHEMBL28432314 0.82 KMT2A (0.64) KMT2APOLBMEN1ALDH1A1TDP1
SCHEMBL3616463 0.81 SMN1; SMN2 (0.67) KMT2APOLBMEN1ALDH1A1LMNA
SCHEMBL29915528 0.79 ALDH1A1 (0.71) KMT2AMEN1ALDH1A1TDP1THRB
SCHEMBL1242243 0.79 ALDH1A1 (0.71) KMT2AMEN1ALDH1A1TDP1THRB
SCHEMBL3953437 0.77 ALDH1A1 (0.73) KMT2APOLBMEN1ALDH1A1TDP1
Hydrochloric Acid SCHEMBL27841975 0.77 ALDH1A1 (0.68) KMT2AMEN1ALDH1A1TDP1THRB
SCHEMBL11738301 0.76 KMT2A (0.50) KMT2APOLBMEN1ALDH1A1TDP1
SCHEMBL15354269 0.75 ALDH1A1 (1.00) KMT2APOLBMEN1ALDH1A1TDP1
SCHEMBL7932102 0.75 ALDH1A1 (0.63) KMT2APOLBMEN1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022148459-A1 CLASS OF NOVEL SMAD3 PROTEIN DEGRADERS AND APPLICATION THEREOF 和径医药科技(上海)有限公司 2022-07-14 WO disclosed
US-10294212-B2 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. (IN) 2019-05-21 US disclosed
US-10294212-B2 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. (IN) 2019-05-21 US disclosed
EP-2970173-B1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD (IN) 2018-05-09 EP disclosed
EP-2970173-B1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD (IN) 2018-05-09 EP disclosed
US-20180030026-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PVT LTD 2018-02-01 US disclosed
US-20180030026-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PVT LTD 2018-02-01 US disclosed
US-20180030026-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PVT LTD 2018-02-01 US disclosed
US-9815811-B2 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. (IN) 2017-11-14 US disclosed
US-9815811-B2 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. (IN) 2017-11-14 US disclosed
US-9815811-B2 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. (IN) 2017-11-14 US disclosed
US-20160046596-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD. (IN) 2016-02-18 US disclosed
US-20160046596-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD. (IN) 2016-02-18 US disclosed
US-20160046596-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD. (IN) 2016-02-18 US disclosed
EP-2970173-A1 INHIBITORS OF THE KYNURENINE PATHWAY Curadev Pharma Private Ltd. (IN) 2016-01-20 EP disclosed
WO-2014186035-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD. (IN) 2014-11-20 WO disclosed
WO-2014186035-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD. (IN) 2014-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294212-B2 Inhibitors of the kynurenine pathway IDO1, IDO2, KYNU KMT2A 952/4885POLB 2557/4885MEN1 2706/4885
US-20180030026-A1 INHIBITORS OF THE KYNURENINE PATHWAY IDO1, IDO2, KYNU KMT2A 952/4885POLB 2557/4885MEN1 2706/4885
US-20160046596-A1 INHIBITORS OF THE KYNURENINE PATHWAY IDO1, KYNU, IDO2 KMT2A 848/4885POLB 3696/4885MEN1 2596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.